

# Coronavirus and birth in Italy: results of a national population-based cohort study

Alice Maraschini<sup>1</sup>, Edoardo Corsi<sup>2</sup>, Michele Antonio Salvatore<sup>1</sup>, Serena Donati<sup>1</sup>  
and the ItOSS COVID-19 Working Group\*

<sup>1</sup>Centro Nazionale di Prevenzione delle Malattie e Promozione della Salute, Istituto Superiore di Sanità, Rome, Italy

<sup>2</sup>Dipartimento di Biomedicina e Prevenzione, Università degli Studi Tor Vergata, Rome, Italy

\*the members of the ItOSS COVID-19 Working Group are reported before the References

## Abstract

**Introduction.** The study was implemented to provide guidance to decision-makers and clinicians by describing hospital care offered to women who gave birth with confirmed SARS-CoV-2 infection.

**Materials and methods.** National population-based prospective cohort study involving all women with confirmed SARS-CoV-2 infection who gave birth between February 25 and April 22, 2020 in any Italian hospital.

**Results.** The incidence rate of confirmed SARS-CoV-2 infection in women who gave birth was 2.1 per 1000 maternities at a national level and 6.9/1000 in the Lombardy Region. Overall one third of the women developed a pneumonia and 49.7% assumed at least one drug against SARS-CoV-2 infection. Caesarean rate was 32.9%, no mothers nor newborns died. Six percent of the infants tested positive for SARS-CoV-2 at birth.

**Conclusions.** Clinical features and outcomes of COVID-19 in women who gave birth are similar to those described for the general population, most women developing mild to moderate illness.

## Key words

- pregnancy
- SARS-CoV-2
- pregnancy outcome
- COVID-19
- cohort studies

## INTRODUCTION

Following the Chinese epidemic, Italy is currently one of the European countries reporting the highest number of clinical cases. From the H1N1 influenza, SARS, and MERS outbreaks, we learned that pregnant women are at higher risk of developing respiratory complications as well as worse maternal and neonatal outcomes [1]. Although there is no conclusive information with regards to an increased susceptibility of pregnant women to the SARS-CoV-2 illness, the currently available data suggest that it is analogous to that of the general population [1, 2].

To date, there have been several published case series of deliveries among women affected by COVID-19 [3-6]. Available data come primarily from China, and the UK [4].

There is a critical need to develop clinical guidance for obstetric providers and neonatologists, and this should be based on rigorously collected data. The Italian Obstetric Surveillance System (ItOSS) [7] is convenient for establishing a national prospective population-

based cohort study on COVID-19 in pregnancy, birth and postpartum in Italy.

This paper describes hospital care of pregnant women with confirmed SARS-CoV-2 infection admitted to Italian hospitals for childbirth. Possible transmission of the SARS-CoV-2 virus from mothers to newborns is also addressed.

## MATERIALS AND METHODS

The ItOSS national population-based cohort study collects information on all women who gave birth in any Italian hospital with a SARS-CoV-2 infection confirmed during pregnancy. The methods set forth in the study protocol for the diagnosis includes: reverse transcriptase-polymerase chain reaction (RT-PCR) testing for the SARS-CoV-2 virus through a nasopharyngeal swab and/or chest X-ray or computer tomography (CT) features of COVID-19 pneumonia and/or antibody response to SARS-CoV-2 from maternal peripheral blood.

The study's core outcomes include incidence rate of SARS-CoV-2 infection estimate, COVID-19 pneumo-

nia, preterm birth, mode of delivery, invasive respiratory support, intensive care unit (ICU) admission, and maternal and neonatal severe morbidity and mortality.

The ItOSS network of trained reference clinicians working in Italian public and private maternity units covering 91% of total births [7] has been extended to reach nationwide coverage for the present study. Through this system, cases are rapidly notified and data on maternal and neonatal management collected. Informed consent to the participation is acquired from any woman at study enrolment.

A multidisciplinary expert group of clinicians has revised the data entry form and its online version has been pre-tested. The form is designed to collect information regarding the woman's socio-demographic characteristics, medical and obstetrical history, pneumonia diagnosis and treatment, mode of delivery, and maternal and neonatal outcomes.

In case of maternal death from SARS-CoV-2 infection, the ItOSS maternal mortality surveillance system will allow verification and provide further information.

Since this is an observational study, the cohort size depends on the incidence of the disease; therefore, a formal power calculation has not been performed.

The data are collected and processed by personnel responsible for ensuring confidentiality and security. This analysis reports hospitalized cases from February 25 to April 22, 2020, for whom complete data have been received by April 11, 2020.

The incidence rates of women with confirmed SARS-CoV-2 infection who gave birth with a 95% confidence interval (CI) were estimated at a national level, by geographical area, and for the Lombardy Region. Denominator estimates are based on the national Birth Registry providing the most recent available data on deliveries (year 2018) assuming an annual reduction of 3% in births. The data analysis focuses on descriptive statistics stratified by the occurrence of pneumonia. Significant differences between the two groups were assessed through the Pearson's Chi-squared test or the Fisher's exact test for categorical variables and the Mann-Whitney U test for continuous variables. Data analyses were performed at the Italian National Health Institute using the Statistical Package Stata/MP 14.2.

The Ethics Committee of the Italian National Institute of Health approved the project (Prot. 0010482 CE 01.00, Rome 24/03/2020).

This study has not received any funding.

## RESULTS

From February 25 to April 22, 2020, 146 women who gave birth in any Italian Obstetric Unit with confirmed SARS-CoV-2 infection during pregnancy were notified to ItOSS. The diagnosis of SARS-CoV-2 infection was confirmed for 142 patients by RT-PCR testing through nasopharyngeal swab and in 4 cases through chest X-ray.

Out of the total cases, 126 (86.3%) were notified by 5 Regions and 2 Autonomous Provinces located in the North of the country. Among the cases reported in the North, 84 (57.5%) were identified in the Lombardy Region.

Among an estimated 70 343 maternities that took

place over the same study period in Italy, the incidence rate of confirmed SARS-CoV-2 infection in women who gave birth was 2.1 per 1000 (CI 95% 1.8-2.4) maternities at a national level, 3.9/1000 (CI 95% 3.2-4.6) in Northern, 1.0/1000 (CI 95% 0.6-1.6) in Central, and 0.2/1000 (CI 95% 0.1-0.5) in Southern Italy. The rate in Lombardy was 6.9/1000 (CI 95% 5.5-8.5) maternities.

During the 14 days prior to diagnosis, 41.1% of the women reported having had contact with a probable case (32.9%) or entering health care facilities with confirmed SARS-CoV-2 cases (13.7%).

*Table 1* describes the socio-demographic characteristics of the cohort stratified by COVID-19 pneumonia occurrence. Women's median age is 32 years (q1-q3 = 29-36). Women without Italian citizenship are 18.5% of the entire cohort, respectively 27.7% and 14.4% of the group with and without pneumonia (*p*-value = 0.049). Previous comorbidities were significantly higher (*p*-value = 0.023) amongst the pneumonia group (34.0%) compared to unaffected women (17.2%), obesity being the most frequent condition. None of the women smoked until the end of pregnancy, and foetal growth restriction was diagnosed in 2.0% of the cases.

As reported in *Table 2*, multiparas are 69.2% of the cohort and 67.1% of the mothers gave birth vaginally, 25.5% under epidural analgesia. Caesarean section (CS) rate was 32.9% overall, 48.9% among the pneumonia group and 25.3% among the unaffected group (*p*-value = 0.004). COVID-19 indication to CS concerned 7.5% of the entire cohort. General anaesthesia was performed in 5 cases.

Overall, 19.2% of the cohort gave birth preterm, 12.3% due to spontaneous onset of preterm delivery (*n* = 18), and 6.9% due to iatrogenic labour induction (*n* = 3) and urgent/emergency CS (*n* = 7). Preterm birth <37 weeks concerned 31.9% of the women affected by pneumonia compared to 13.1% of the unaffected (*p*-value = 0.007). Among preterm births, the majority were late preterm (*Table 2*).

On hospital admission, 28.1% of the women were asymptomatic. The onset of clinical symptoms occurred in 9.5% of the cases on the day of delivery, and in 90.5% before it, the median value being 8 days (range 1-52 days). Overall, fever (47.9%), cough (46.6%), and general weakness (35.6%) were the most common symptoms at presentation. *Table 3* highlights the higher percentage of symptoms amongst women affected by pneumonia, 31.9% reporting dyspnoea vs 5.1% of the unaffected (*p*-value <0.001).

One third of the women developed COVID-19 pneumonia; oxygen saturation <95% and abnormal results of blood gas test concerned respectively 27.7% and 35.6% of the women with pneumonia compared to 4% of the unaffected.

Over 80% of the women who developed pneumonia received at least one pharmacological treatment (*Table 3*), hydroxychloroquine was the most frequently administered drug alone (4.3%) and in combination with other medical therapies (69.6%). The most frequently adopted therapeutic scheme included hydroxychloroquine in association with antivirals and antibiotics concerning 13.8% of the cohort and 37.0% of the group

**Table 1**

Women's socio-demographic characteristics by occurrence of COVID-19 pneumonia

Characteristics	Total (N = 146)		No COVID-19 pneumonia (N = 99)		COVID-19 pneumonia (N = 47)		p-value
	n	%	n	%	n	%	
<b>Maternal age<sup>a</sup></b>							
<30	40	(28.0)	23	(24.0)	17	(36.2)	0.174
30-34	53	(37.1)	35	(36.5)	18	(38.3)	
≥35	50	(35.0)	38	(39.6)	12	(25.5)	
<b>Citizenship</b>							
Not Italian	27	(18.5)	14	(14.1)	13	(27.7)	0.049
Italian	119	(81.5)	85	(85.9)	34	(72.3)	
<b>Country of birth</b>							
Italy and western Europe	112	(76.7)	83	(83.8)	29	(61.7)	0.010
East Europe	10	(6.8)	7	(7.1)	3	(6.4)	
Africa	9	(6.2)	4	(4.0)	5	(10.6)	
South/Central America	11	(7.5)	4	(4.0)	7	(14.9)	
Asia	4	(2.7)	1	(1.0)	3	(6.4)	
<b>Educational level</b>							
≤8 years	18	(12.3)	10	(10.1)	8	(17.0)	0.469
>8 years	86	(58.9)	59	(59.6)	27	(57.4)	
Missing	42	(28.8)	30	(30.3)	12	(25.5)	
<b>Previous comorbidities</b>							
No	113	(77.4)	82	(82.8)	31	(66.0)	0.023
Yes	33	(22.6)	17	(17.2)	16	(34.0)	
Obesity	22	(15.1)	11	(11.1)	11	(23.4)	0.067
Autoimmune disease	4	(2.7)	2	(2.0)	2	(4.3)	0.387
Diabetes	6	(4.1)	4	(4.0)	2	(4.3)	0.649
Hypertension	5	(3.4)	1	(1.0)	4	(8.5)	0.042
Other	3	(2.1)	2	(2.0)	1	(2.1)	0.691
<b>Smoking in pregnancy</b>							
Never	118	(80.8)	78	(78.8)	40	(85.1)	0.719
Quit before or during pregnancy	14	(9.6)	11	(11.1)	3	(2.1)	
Missing	14	(9.6)	10	(10.1)	4	(8.5)	

<sup>a</sup> 3 missing values in "No COVID-19 pneumonia" group.

with pneumonia. Among women with pneumonia, the subgroup at higher risk of worse outcomes – defined by the presence of at least one previous comorbidity or C-reactive protein >10mg/100ml or dyspnoea – received more often the combination of the three drugs. The women belonging to this subgroup, compared to those at lower risk, registered the longest hospital stay (median value 13 days), received more often invasive ventilatory support due to severe morbidity and were admitted more frequently to ICU.

Antenatal corticosteroids for foetal lung maturation were administered respectively to 10.9% and 4.0% of the groups with and without pneumonia.

Severe adverse maternal outcomes have been rare, affecting almost exclusively the group with pneumonia, as described in *Table 4*. Seven women (4.8%) were in critical

conditions due to severe morbidity (2 acute respiratory distress syndromes, 1 respiratory failure, 1 preeclampsia, 2 postpartum haemorrhages, and one thrombosis). Invasive ventilatory support concerned 11 women (7.5%), orotracheal intubation 2 mothers (1.4%). ICU admission regarded 7 patients (4.8%), on average for 7 days. None required extracorporeal membrane oxygenation and none died. Two percent of the women were transferred from another hospital, and 18 were still hospitalized at the end of the study period. The median hospital stay was respectively 10 and 4 days for the women with and without pneumonia (*p*-value <0.001).

Overall, 2 stillbirths were detected respectively at 30 and 35 weeks of pregnancy (*Table 5*). There were 143 singletons and 3 sets of twins, 85.0% of the newborns weighed ≥2500 gr, 3.4% <1500 gr. Median Apgar index

**Table 2**

Obstetric characteristics by occurrence of COVID-19 pneumonia

Characteristics	Total (N = 146)		No COVID-19 pneumonia (N = 99)		COVID-19 pneumonia (N = 47)		p-value
	n	%	n	%	n	%	
<b>Parity</b>							
Nulliparae	45	(30.8)	32	(32.3)	13	(27.7)	0.569
Multiparae	101	(69.2)	67	(67.7)	34	(72.3)	
<b>Multiple pregnancy</b>							
No	143	(97.9)	97	(98.0)	46	(97.9)	0.691
Yes	3	(2.1)	2	(2.0)	1	(2.1)	
<b>Mode of delivery</b>							
Vaginal	98	(67.1)	74	(74.7)	24	(51.1)	0.001
Elective CS	12	(8.2)	9	(9.1)	3	(6.4)	
Urgent/emergency CS due to maternal/foetal indication	25	(17.1)	14	(14.1)	11	(23.4)	
Urgent/emergency CS due to COVID-19	11	(7.5)	2	(2.0)	9	(19.1)	
<b>PPROM<sup>a</sup></b>							
No	134	(95.0)	90	(94.7)	44	(95.7)	0.587
Yes	7	(5.0)	5	(5.3)	2	(4.3)	
<b>Gestational age at birth</b>							
≤32	6	(4.1)	2	(2.0)	4	(8.5)	0.017
33-36	22	(15.1)	11	(11.1)	11	(23.4)	
≥37	118	(80.8)	86	(86.9)	32	(68.1)	
Median (q1-q3)	38	(37-39)	38	(37-40)	38	(36-39)	

CS: Caesarean Section; PPROM: Preterm Premature Rupture of Membranes; q1: 25% percentile; q3: 75% percentile.

<sup>a</sup> 5 missing values (4 in "No COVID-19 pneumonia" group and 1 in "COVID-19 pneumonia" group).

was 9 at 1 minute and 10 at 5 minutes; at 5 minutes, 1 infant had Apgar index <4 (*Table 4*). Admission to neonatal intensive care unit (NICU) concerned 23 newborns (15.6%), 18 of whom were preterm, including 6 <32 weeks of gestation. Four infants developed severe morbidity (1 interstitial pneumonia and 3 respiratory distress syndrome). Two were breeches, one affected by spina bifida, and one was macrosoma. None of them tested SARS-CoV-2 positive at birth and, overall, no neonatal death was recorded.

Nine newborns (6.1%) tested positive for SARS-CoV-2, 5 were tested on the day of delivery, 1 the day after, and 3 after 6-9 days from birth. Out of the 5 newborns with positive swabs collected within 24 hours from birth, 4 were delivered vaginally and 1 by pre-labour CS. Three of the positive infants were admitted to NICU, and none of them developed a severe illness.

## DISCUSSION

The incidence rates of SARS-CoV-2 positive women who gave birth in Italy (2.1/1000), in the North (3.9/1000), the Centre (1/1000) and the South of the country (0.2/1000) as well as in the Lombardy Region (6.9/1000) reflect the same variation in circulation of the virus among geographical areas as that detected in the general population [8]. This observation impacts on the present different seroprevalence and susceptibil-

ity of the population. In the current phase, following the lockdown, the early identification of new cases and their contact traceability and isolation will be decisive for the containment of the virus circulation.

Compared to the reference population of women giving birth in Northern Italy [9, 10], the higher proportion of multiparas (69% vs 50%) among the women with SARS-CoV-2 infection confirms the hypothesis of greater circulation of the virus in families with children who are often asymptomatic.

Clinical features of the detected pneumonia are similar to those described by previous studies [2, 6, 11, 12]. The majority of cases are mild/moderate, and similarly to the UKOSS study [4] previous comorbidities are significantly associated with pneumonia (*p*-value = 0.023).

In Italy, black and minority ethnicities are present in a lower proportion than in the UK where a significant association with COVID-19 has been detected [4]. Hospitalized women without Italian citizenship develop significantly more often pneumonia than the Italians (*p*-value = 0.049), probably due to delayed access to healthcare services.

Preterm birth, which is one of the feared outcomes of COVID-19, was overall 21.2% in the UK cohort [4], 17.4% in the WHO review [6], and 19.2% in Italy compared to the 7% figure among women who gave birth in northern Italy [8, 9].

**Table 3**

Diagnosis and medical therapy by occurrence of COVID-19 pneumonia

Characteristics	Total (N = 146)		No COVID-19 pneumonia (N = 99)		COVID-19 pneumonia (N = 47)		p-value
	n	%	n	%	n	%	
<b>Symptoms</b>							
Fever	70	(47.9)	39	(39.4)	31	(66.0)	0.003
Cough	68	(46.6)	38	(38.4)	30	(63.8)	0.004
Tiredness	52	(35.6)	25	(25.3)	27	(57.4)	<0.001
Muscle/joint pain	28	(19.2)	14	(14.1)	14	(29.8)	0.015
Sore throat	27	(18.5)	16	(16.2)	11	(23.4)	0.261
Rhinorrhea	23	(15.8)	17	(17.2)	6	(12.8)	0.528
Dyspnea	20	(13.7)	5	(5.1)	15	(31.9)	<0.001
Headache	16	(11.0)	7	(7.1)	9	(19.1)	0.024
Vomiting/Diarrhea	14	(9.6)	5	(5.1)	9	(19.1)	0.005
Chest pain	5	(3.4)	3	(3.0)	2	(4.3)	0.650
Conjunctivitis	3	(2.1)	3	(3.0)	0	(0.0)	0.553
No symptoms	41	(28.1)	37	(37.4)	4	(8.5)	<0.001
<b>Imaging techniques</b>							
No exams	62	(42.5)	62	(62.6)	0	(0.0)	<0.001
Chest X-ray	51	(34.9)	26	(26.3)	25	(53.2)	
Chest CT	6	(4.1)	2	(2.0)	4	(8.5)	
Lung ultrasound	6	(4.1)	5	(5.1)	1	(2.1)	
Association of different techniques	21	(14.4)	4	(4.0)	17	(36.2)	
<b>Vital signs and laboratory reports</b>							
Body temperature >37.5 °C	34	(23.3)	11	(11.1)	23	(48.9)	<0.001
Lymphopenia (<1500 mm3)	73	(50.0)	40	(40.4)	33	(70.2)	0.008
CRP values >10mg/100ml	34	(23.3)	17	(17.2)	17	(36.2)	0.077
Oxygen saturation <95%	17	(11.6)	4	(4.0)	13	(27.7)	<0.001
Blood gas test <sup>a</sup>							
Not performed	96	(67.6)	80	(82.5)	16	(35.6)	<0.001
Performed. normal results	26	(18.3)	13	(13.4)	13	(28.9)	
Performed. abnormal results	20	(14.1)	4	(4.1)	16	(35.6)	
Drugs administered <sup>b</sup>							
HCQ + Antivirals + Antibiotics	20	(13.8)	3	(3.0)	17	(37.0)	<0.001
HCQ + Antibiotics	14	(9.7)	6	(6.1)	8	(17.4)	
Empirical antibiotics	14	(9.7)	12	(12.1)	2	(4.3)	
HCQ + Antivirals	8	(5.5)	1	(1.0)	7	(15.2)	
HCQ alone	8	(5.5)	6	(6.1)	2	(4.3)	
Antivirals + Antibiotics	5	(3.4)	1	(1.0)	4	(8.7)	
Targeted antibiotics	2	(1.4)	2	(2.0)	0	(0.0)	
Antivirals alone	1	(0.7)	1	(1.0)	0	(0.0)	
No pharmacological treatment	73	(50.3)	67	(67.7)	6	(13.0)	
Antenatal corticosteroids	9	(6.2)	4	(4.0)	5	(10.9)	0.132

CRP: C-reactive protein; CT: Computed tomography; HCQ: hydroxychloroquine.

<sup>a</sup> 4 missing values (2 in "No COVID-19 pneumonia" group and 2 in "COVID-19 pneumonia" group).<sup>b</sup> 1 missing value in "COVID-19 pneumonia" group.

**Table 4**

Maternal outcomes by occurrence of COVID-19 pneumonia

Characteristics	Total (N = 146)		No COVID-19 pneumonia (N = 99)		COVID-19 pneumonia (N = 47)		p-value
	n	%	n	%	n	%	
Severe morbidity	7	(4.8)	3	(3.0)	4	(8.5)	0.215
Non invasive respiratory support	28	(19.2)	6	(6.1)	22	(46.8)	<0.001
Invasive respiratory support	11	(7.5)	2	(2.0)	9	(19.1)	0.001
Orotracheal intubation	2	(1.4)	1	(1.0)	1	(2.1)	0.544
ICU admission	7	(4.8)	2	(2.0)	5	(10.6)	0.035
Extracorporeal membrane oxygenation	0	(0.0)	0	(0.0)	0	(0.0)	-
Maternal death	0	(0.0)	0	(0.0)	0	(0.0)	-

ICU: Intensive Care Unit.

**Table 5**

Foetal and neonatal outcomes by occurrence of COVID-19 pneumonia

Characteristics	Total (N = 149)		No COVID-19 pneumonia (N = 101)		COVID-19 pneumonia (N = 48)		p-value
	n	%	n	%	n	%	
Stillbirth	2	(1.3)	1	(1.0)	1	(2.1)	0.542
Livebirth	147	(98.7)	100	(99.0)	47	(97.9)	
Neonatal birthweight (g)							
<1500	5	(3.4)	3	(3.0)	2	(4.3)	0.267
1500-2499	17	(11.6)	9	(9.0)	8	(17.0)	
≥2500	125	(85.0)	88	(88.0)	37	(78.7)	
Apgar 1 min >7	128	(87.1)	91	(91.0)	37	(78.7)	0.039
Apgar 5 min >7	140	(95.2)	98	(98.0)	42	(89.4)	0.022
NICU admission	23	(15.6)	10	(10.0)	13	(27.7)	0.007
Neonatal morbidity	4	(2.7)	1	(1.0)	3	(6.4)	0.106
Neonatal death	0	(0.0)	0	(0.0)	0	(0.0)	
Neonatal positive SARS-CoV-2 test							
No	138	(93.9)	94	(94.0)	44	(93.6)	0.594
Positive test <24 hrs of age	5	(3.4)	4	(4.0)	1	(2.1)	
Positive test ≥24 hrs of age	4	(2.7)	2	(2.0)	2	(4.3)	

NICU: Neonatal Intensive Care Unit.

Mothers requiring critical care were 9% in the UK [4] and 7.5% in Italy. NICU admissions concerned respectively 26% in the UK [4], 6.2% of the infants described by the WHO review [6], and 4.8% of the Italian newborns (*Table 4*) but this variability could be related to different local admission policies to NICU regarding quarantine or neonatal observation. The UK cohort reported 5 maternal and 2 neonatal deaths compared to zero deaths reported in Italy and China. The interpretation of these differences is not straightforward even though the lower prevalence of minority ethnicities could play a role as well as the different pattern of drug prescriptions.

The data are preliminary and collection is still ongoing; nevertheless, they confirm a better course of the disease compared to H1N1 flu and SARS and MERS epidemics [1, 2].

The observation that almost 60% of the enrolled women did not have risky contacts during the 14 days prior to symptom onset raises the challenge of the impact of asymptomatic infections and the opportunity to consider screening policies for pregnant women at hospital admission, currently available in few Italian Regions and/or hospitals.

The proportion of women with pneumonia receiving pharmacological treatment against SARS-CoV-2 infection in this study is high, 73.9% receiving hydroxychloroquine alone or in association with antivirals and/or empirical antibiotics (*Table 3*). Lopinavir amongst antivirals is the most frequently used, probably due to the experience of its use in HIV positive women. No differences on maternal and neonatal outcomes have been detected according to the drugs administered.

Conversely, among the UKOSS cohort hydroxychloroquine was not administered at all and 2% of the women received antivirals [4]. At the end of May, the Italian Medicines Agency (AIFA) suspended the authorization for the prescription by the National Health Service of hydroxychloroquine and lopinavir/ritonavir for COVID-19, except for use in clinical studies. It is necessary to study safety and effectiveness of medications used in pregnant women to guide decision-making about treatment options for COVID-19 disease and associated complications.

Antenatal corticosteroids for foetal lung maturation have been prescribed as recommended [2] to 4 women <34 weeks and to 5 women at 34–35 weeks of gestation.

The detected rate of CS in the Italian cohort is 32.9%, higher compared to the rate of the Northern Regions (26%) but considerably lower compared to 59% of the UK cohort [4], 73.5% reported by the WHO review [6], and 85% of the Chinese series [3–6]. As reported in the UK, the majority of CS indications were not due to SARS-CoV-2 infection, which is not in itself necessarily an indication for delivery, nor for CS. The proportion of CS due to COVID-19 concerned in fact a minority of the total surgeries, 7.5% of Italian and 16% of UK cohort. Although international agencies are unequivocal in claiming that the disease is not an indication for CS and that the protection of birth physiology is a priority [2, 13, 14], clinical practice seem not to follow the current recommendations. Italy, which has historically recorded higher CS rates compared to the UK, on this occasion didn't show the same significant increase in CS as in other countries despite the early onset of the epidemic.

An issue still highly debated concerns the possibility of mother to foetus transmission of SARS-CoV-2 virus. The WHO review shows that 6.6% of the newborns tested as suspected to have COVID-19, the UK cohort reports 5% of positive infants, and the ItOSS cohort 6%. Although evidence is sparse, vertical transmission cannot be excluded [15, 16] but it appears to be rare and, for the most part, babies, who must be carefully monitored, have a good prognosis.

Many case reports and small case series have already been published on COVID-19 in pregnancy; however, there is a lack of population-based data that could allow incidence rates to be estimated and unbiased characteristics and outcomes to be described and compared [4]. The scientific community, as well as international journal peer review procedures, should better support the development and the dissemination of studies adopting population-based approaches to properly inform clinicians and decision-makers.

Pregnant women are often not included in clinical trials on drugs [17]. However, the good news is that recently the European Medicines Agency and Health Canada under the aegis of the International Coalition of Medicines Regulatory Authorities have agreed on three priority areas for cooperation on observational research during the outbreak of COVID-19 [18]. One area is devoted to research in pregnancy in order to examine the impact of both Coronavirus disease and the use of drugs on pregnant women infected with SARS-CoV-2 and their unborn babies. The different practices in pre-

scribing hydroxychloroquine and antivirals observed in the UK and Italy promotes a reflection on the determining factors that guide clinicians in deciding whether and to what extent they should confidently prescribe drugs for which conclusive evidence is still unavailable.

The study's strengths are the national population-based prospective design and the opportunity to analyse data from the beginning of the epidemic. Another asset is the wealth of information contained in the data collection form. Limitations include the analysis of preliminary data while the pandemic is still underway and the constraints linked to the impossibility of generalizing the results without taking into account the different prevalence of the condition by geographical area. The lack of information regarding women infected in the early stages of pregnancy is also a limit of the study, but the ItOSS will follow-up affected women currently in the first trimester of pregnancy.

## CONCLUSIONS

The clinical presentation of SARS-CoV-2 infection in women who gave birth appears to be similar to the general population. The lesson learned by reviewing hospital care offered to affected Italian women who gave birth, confirmed the current priority of physical distancing measures, the urgent need for stronger evidence on the safety and effectiveness of medical therapy and a continued commitment to face the challenge of respecting and protecting childbirth physiology. These findings confirm the primary importance of comparisons among population-based cohorts to support health professionals and decision-makers with evidence-based recommendations.

## Acknowledgements

We thank Silvia Andreozzi and Mauro Bucciarelli for their valuable technical support and assistance to the operation of the web-based data collection system. We thank Clarissa Bostford for language editing.

Our heartfelt thanks go to all the clinicians working in the national network of maternity units (*Appendix*) for the assistance offered to women and for collecting the data, we thank all women who agreed to participate in the study.

## Disclosure statement

The Authors and the working group members report no conflict of interest.

## Source of financial support

This study has not received any financial support.

## Individual contribution to the manuscript

Alice Maraschini: conceptualization, methodology, software, formal analysis, writing-review and editing; Edoardo Corsi: methodology, investigation, data curation, writing-review and editing, project administration; Michele Antonio Salvatore: methodology, formal analysis, writing-review and editing; Serena Donati: conceptualization, methodology, formal analysis, writing original draft, supervision; Ilaria Lega: investigation, writing-review and editing; Paola D'Aloja: investigation,

writing-review and editing; Letizia Sampaolo: literature review, writing-review and editing; Paola Casucci: investigation, data curation; Irene Cetin: investigation, data curation; Gabriella Dardanoni: investigation, data curation; Franco Doganiero: investigation; Enrico Ferrazzi: investigation, data curation; Massimo Piergiuseppe Franchi: investigation, data curation; Livio Leo: investigation, data curation; Marco Liberati: investigation, data curation; Mariavittoria Locci: investigation, data curation; Claudio Martini: investigation, data curation; Federico Mecacci: investigation, data curation; Alessandra Meloni: investigation, data curation; Anna Domenica Mignuoli: investigation, data curation; Luisa Mondo: investigation, data curation; Luisa Patanè: investigation, data curation; Enrica Perrone: investigation, data curation, writing review and editing; Federico Prefumo: investigation, data curation; Luca Ramenghi: investigation, data curation; Valeria Savasi: investigation, data curation; Sergio Schettini: investigation, data curation; Martin Steinkasserer: investigation, data curation; Saverio Tateo: investigation, data curation; Vito Trojano: investigation, data curation; Patrizia Vergani: investigation, data curation.

### **The ItOSS COVID-19 Working Group**

Serena Donati<sup>1</sup>, Alice Maraschini<sup>1</sup>, Ilaria Lega<sup>1</sup>, Paola D'Aloja<sup>1</sup>, Letizia Sampaolo<sup>1</sup>, Michele Antonio Salvatore<sup>1</sup>, Edoardo Corsi<sup>2</sup>, Salvatore Alberico<sup>3</sup>, Paola Casucci<sup>4</sup>, Irene Cetin<sup>5</sup>, Gabriella Dardanoni<sup>6</sup>, Franco Doganiero<sup>7</sup>, Massimo Piergiuseppe Franchi<sup>8</sup>, Enrico Ferrazzi<sup>9</sup>, Livio Leo<sup>10</sup>, Marco Liberati<sup>11</sup>, Mariavittoria Locci<sup>12</sup>, Claudio Martini<sup>13</sup>, Federico Mecacci<sup>14</sup>, Alessandra Meloni<sup>15</sup>, Anna Domenica Mignuoli<sup>16</sup>, Luisa Mondo<sup>17</sup>, Luisa Patanè<sup>18</sup>, Enrica Perrone<sup>19</sup>, Federico Prefumo<sup>20</sup>, Luca Ramenghi<sup>21</sup>, Valeria Savasi<sup>22</sup>, Sergio Schettini<sup>23</sup>, Martin Steinkasserer<sup>24</sup>, Saverio Tateo<sup>25</sup>, Vito Trojano<sup>26</sup>, Patrizia Vergani<sup>27</sup>

<sup>1</sup>Centro Nazionale di Prevenzione delle Malattie e Promozione della Salute, Istituto Superiore di Sanità, Rome, Italy

<sup>2</sup>Dipartimento di Biomedicina e Prevenzione, Università di Roma Tor Vergata, Rome, Italy

<sup>3</sup>IRCCS Burlo Garofolo, Trieste, Italy

<sup>4</sup>Regione Umbria, Perugia, Italy

<sup>5</sup>Università degli Studi di Milano, Milan, Italy

<sup>6</sup>Regione Sicilia, Palermo, Italy

<sup>7</sup>Ospedale Civile Antonio Cardarelli, Campobasso, Italy

<sup>8</sup>Università degli Studi di Verona, Verona, Italy

<sup>9</sup>Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico Milan, Italy

<sup>10</sup>Ospedale Beauregard Valle D'Aosta, Aosta, Italy

<sup>11</sup>Università degli Studi Gabriele d'Annunzio, Chieti-Pescara, Italy

<sup>12</sup>Università degli Studi di Napoli Federico II, Naples, Italy

<sup>13</sup>Regione Marche, Ancona, Italy

<sup>14</sup>Università degli Studi di Firenze, Florence, Italy

<sup>15</sup>Regione Autonoma della Sardegna, Cagliari, Italy

<sup>16</sup>Regione Calabria, Reggio Calabria, Italy

<sup>17</sup>ASL TO<sup>3</sup>, Turin, Italy

<sup>18</sup>ASST Papa Giovanni XXII, Bergamo, Italy

<sup>19</sup>Regione Emilia-Romagna, Bologna, Italy

<sup>20</sup>ASST Spedali Civili di Brescia, Italy

<sup>21</sup>IRCSS Giannina Gaslini, Genoa, Rome

<sup>22</sup>ASST Fatebenefratelli Sacco, Milan, Italy

<sup>23</sup>Azienda Ospedaliera S. Carlo, Potenza, Italy

<sup>24</sup>Ospedale Centrale di Bolzano, Bozen, Italy

<sup>25</sup>Ospedale Santa Chiara, Trento, Italy

<sup>26</sup>Mater Dei Hospital, Bari, Italy

<sup>27</sup>Fondazione MBBM/Ospedale San Gerardo, Monza, Italy

Received on 9 June 2020.

Accepted on 16 July 2020.

### **APPENDIX. Reference clinicians and maternity units participating in the project network**

#### **Piemonte**

Elena Amoruso Ospedale Sant'Andrea Vercelli; Alberto Arnulfo, Enrico Finale Stabilimento Ospedaliero Castelli Verbania; Maria Bertolino, Andrea Guala Ospedale San Biagio Domodossola; Marisa Biasio, Ruggero Crocco, Pietro Gaglioti, Luca Marozio, Clara Monzeglio Sant'Anna - AOU Città della Salute e della Scienza di Torino; Mario Canesi, Sara Cantoira Ospedale Maria Vittoria Torino; Paola Capelli Istituto SS. Trinità Borgomanero; Ilaria Careri, Giovanni Lipari Ospedale Martini Torino; Luigi Carratta Ospedale S. Spirito Casale Monferrato; Ilaria Costaggini Ospedale degli Inferni Rivoli; Tania Cunzolo Presidio Osp. Cardinal G. MASSAIA Asti; Enza De Fabiani Azienda Ospedaliera Ordine Mauriziano Torino; Alberto De Pedrini Ospedale Maggiore della Carità Novara; Fiorenza Droghini, Paola Rota Ospedale Santa Croce Moncalieri; Germano Giordano Ospedale SS. Pietro e Paolo Borgosesia; Daniela Kozel Ospedale Civile SS. Antonio e Biagio Alessandria; Vincenzo Lio Ospedale Civico Chivasso; Francesca Maraucci Ospedale degli inferni Biella; Simona Mazzola Ospedale Maggiore Chieri; Maria Milano Ospedale Civile Mondovì; Giovanna Oggi Ospedale maggiore SS. Annunziata Savigliano; Simona Pelissetto Ospedale Civile di Ivrea; Pasqualina Russo Presidio ospedaliero riunito Ciriè; Manuela Scatà Ospedale Civico di San Lazzaro Alba; Federico Tuo Ospedale San Giacomo Novi Ligure/Tortona; Concetta Vardè Ospedale Agnelli Pinerolo; Elena Vasario Azienda Ospedaliera S. Croce e Carle Cuneo

#### **Valle D'Aosta**

Livio Leo Umberto Parini Aosta

#### **Lombardia**

Debora Balestrieri Ospedale di Cittiglio; Federica Baltaro Ospedale Niguarda di Milano; Pietro Barbacini, Elisabetta Venegoni Ospedale di Magenta; Michele Barbato Ospedale di Melegnano; Lorena Barbetti Ospedale di Esine; Paolo Beretta Ospedale di Como; Bruno Bersellini Ospedale di Sondrio; Stefano Bianchi Ospedale San Giuseppe di Milano; Giuseppina Bizzoni, Giancarlo Garuti Ospedale di Lodi; Antonia Botrugno Ospedale di Casalmaggiore; Donatella Bresciani Ospedale di

dale di Desenzano; Alessandro Bulfoni Pio X Humanitas di Milano; Carlo Bulgheroni Ospedale di Gallarate; Orlando Caruso, Elena Pinton Ospedale di Chiari; Massimo Ciammella Ospedale di Seriate; Elena Crestani, Giulia Pellizzari Ospedale di Pieve di Coriano; Antonella Cromi Ospedale di Varese; Rosa Di Lauro, Carla Foppoli Ospedale di Sondalo; Patrizia D'Oria, Ospedale di Alzano; Santina Ermito Ospedale di Piario; Massimo Ferdico Ospedale di Vimercate; Maria Fogliani, Guido Stevanazzi Ospedale di Legnano-Cuggiono; Roberto Fogliani Ospedale di Sesto San Giovanni; Ambrogio Frigerio Ospedale di Rho; Eleonora Fumagalli Ospedale Macedonio Melloni ASST FBF-Sacco di Milano; Roberto Garbelli Brescia Istituto Clinico S. Anna; Daniela Gatti Ospedale di Manerbio; Giampaolo Grisolia, Serena Vartialta Ospedale di Mantova; Paolo Guarnerio Ospedale San Carlo di Milano; Enrico Iurlaro IRCCS Cà Grande Ospedale Maggiore Policlinico-Mangiagalli Milano; Stefano Landi Ospedale di Gravedona; Mario Leonardi Ospedale di Iseo; Stefania Livio Ospedale Buzzi ASST FBF-Sacco di Milano; Anna Locatelli Ospedale di Carate; Giuseppe Losa Ospedale di Melzo; Massimo Lovotti Como Valduce; Anna Minelli Ospedale di Gavardo; Luisa Muggiasca Ospedale di Garbagnate; Giuseppe Nucera Ospedale di Busto Arsizio; Guido Orfanotti Ospedale di Desio; Alessandra Ornati Ospedale di Vigevano; Luisa Patanè ASST Papa Giovanni XXIII Bergamo; Antonio Pellegrino Ospedale di Lecco; Francesca Perotti, Arsenio Spinillo Fondazione IRCCS Policlinico San Matteo di Pavia; Ezio Pozzi Ospedale di Broni Stradella- Ospedale di Voghera, Federico Prefumo Spedali Civili di Brescia; Anna Catalano Brescia Fondazione Poliambulanza; Marina Ravizza Ospedale San Paolo di Milano; Aldo Riccardi Ospedale di Cremona; Alessia Chiesa Ospedale di Ponte San Pietro; Tazio Sacconi Ospedale di Asola; Valeria Savasi Ospedale Sacco di Milano; Ubaldo Seghezzi Ospedale di Saronno; Vincenzo Siliprandi Ospedale di Crema; Paolo Valsecchi Ospedale San Raffaele; Laura Vassena Ospedale di Merate; Patrizia Vergani Fondazione MBBM Ospedale San Gerardo Monza; Antonella Villa Ospedale di Treviglio; Matteo Zanfrà Ospedale di Tradate; Alberto Zanini Ospedale di Erba

## Veneto

Giuseppe Angeloni Ospedale di Piove di Sacco; Antonio Azzena Ospedale di Vittorio Veneto; Roberto Bacchiet, Cristina Napolitano Ospedale di Oderzo; Valentino Bergamini Ospedale Borgo Trento; Luca Bergamini Ospedale di Chioggia; Enrico Busato, Monica Zanol Ospedale di Treviso; Pietro Catapano, Marco Gentile Ospedale Mater Salutis - Legnago; Marcello Ceccaroni Ospedale Sacro Cuore don Calabria Negrar; Gianluca Cerri Ospedale SS. Giovanni e Paolo - Venezia; Andrea Cocco Ospedale di Asiago; Enrico Di Mambro Ospedale di Adria - Ospedale di Rovigo; Carlo Dorizzi Ospedale di Schiavonia; Laura Favretti Ospedale S. Maria del Prato - Feltre; Massimo Franchi Azienda Ospedaliera di Verona; Franco Garbin Ospedale di Dolo; Maria Teresa Gervasi, Daniela Truscia Azienda Ospedaliera di Padova; Domenico Lagamba Ospedale di Castelfranco Veneto; Antonino Lo Re Ospedale P. Pederzoli - Casa di cura Privata

Spa; Tiziano Maggino Ospedale all'Angelo di Mestre; Mario Marando Ospedale di Portogruaro e Ospedale di San Donà di Piave; Giovanni Martini Ospedale di Valdagno; Carlo Maurizio Ospedale di Mirano; Yoram J. Meir Ospedale di Bassano del Grappa; Marcello Rigano Ospedale di Camposampiero; Cesare Romagnolo Ospedale di San Bonifacio; Roberto Rulli Ospedale di Cittadella; Maria Grazia Salmeri Ospedale di Montebelluna; Marcello Scollo Ospedale di Santoro; Francesco Sinatra Ospedale di Conegliano; Gianluca Straface Casa di cura Abano; Fabio Gianpaolo Tandurella Ospedale di Pieve di Cadore e Ospedale San Martino - Belluno; Marco Torrazzina Ospedale di Bussolengo - Ospedale di Villafranca; Paolo Lucio Tumaini Ospedale di Arzignano; Giuliano Zanni Ospedale di Vicenza

## Friuli-Venezia Giulia

Emanuele Ancona Pordenone S. Giorgio; Fabiana Cecchini AO Udine; Michela De Agostini Civile Palmanova; Gianpaolo Maso Burlo IRCSS Trieste; Edlira Muharremi Pordenone S.M. degli Angeli; Alessandra Niccoletti S. Daniele - Tolmezzo; Roberta Pinzano AO S.M. degli Angeli S. Vito; Lucia Zanazzo, Monfalcone

## Liguria

Angelo Cagnacci Ospedale S. Martino di Genova; Luca Ramenghi IRCCS Giannina Gaslini di Genova

## Emilia-Romagna

Lorenzo Aguzzoli, Emanuele Soncini Ospedale S.M. Nuova Reggio Emilia; Patrizio Antonazzo, Lucrezia Pignatti Ospedale Bufalini Cesena; Angela Bandini, Isabella Strada Ospedale G.B. Morgagni - L. Pierantoni Forlì; Chiara Belosi Ospedale degli Inferni Faenza; Renza Bonini, Maria Cristina Ottoboni Ospedale Guglielmo Da Saliceto Piacenza; Fabrizio Corazza, Paola Pennacchioni Ospedale Ss. Annunziata Cento; Fabio Facchinetto, Giliana Ternelli Azienda Ospedaliero-Universitaria Modena; Alessandro Ferrari, Cristina Pizzi, Ospedale S.M. Bianca Mirandola; Tiziana Frusca, Stefania Fieni Azienda Ospedaliero-Universitaria Parma; Maria Cristina Galassi, Federica Richieri, Nuovo Ospedale Civile Di Sassuolo S.P.A.; Francesco Giambelli, Carlotta Matteucci Ospedale S.M. Delle Croci Ravenna; Pantaleo Greco, Danila Morano Azienda Ospedaliero-Universitaria Ferrara; Marinella Lenzi, Ilaria Cataneo, Ospedale Maggiore Bologna; Gialuigi Pilu, Marisa Bisulli, Azienda Ospedaliero-Universitaria Bologna; Maria Cristina Selletri Ospedale di Bentivoglio; Federico Spelzini, Elena De Ambrosi, Ospedale degli Inferni Rimini; Paolo Venturini, Francesca Tassinati Ospedale B. Ramazzini Carpi; Stefano Zucchini, Barbara Paccaloni, Ospedale S.M. della Scaletta Imola

## Toscana

Andrea Antonelli, Carlotta Boni Ospedale Civile Cecina; Maria Paola Belluomini, S. Francesco Barga - PO Valle del Serchio e Generale Provinciale Lucca - PO San Luca, Rosalia Bonura, S. Maria della Gruccia - Ospedale del Valdarno, Stefano Braccini, SS. Cosimo e Damiano Pescia - Osp. della Valdinievole, Giacomo Bruscoli e Pasquale Mario Florio, Nuovo Ospedale San Jacopo di Pi-

stoia, Giovanna Casilla, SS. Giacomo e Cristoforo Massa - PO Zona Apuana, Anna Franca Cavaliere, Ospedale Santo Stefano Prato, Marco Cencini, Ospedali Riuniti della Val di Chiana, Venere Coppola e Laura Migliavacca, Ospedale Misericordia Grosseto, Barbara De Santi, PO Felice Lotti Pontedera, Paola Del Carlo, Ospedale S. Giovanni Di Dio Torregalli, Carlo Dettori, Nuovo Ospedale di Borgo S. Lorenzo, Mariarosaria Di Tommaso e Serena Simeone, Careggi - CTO Firenze - AOU, Giuseppe Eremita, Civile Elbano Portoferraio, Sara Failli, Ospedale Area Aretina Nord Arezzo, Paolo Gacci, S.M. Annunziata Bagno a Ripoli - Ospedale Fiorentino Sud Est, Alessandra Meucci, Le Scotte Siena - Azienda ospedaliera universitaria, Filippo Ninni, Riuniti Livorno, Barbara Quirici, Ospedale Unico Versilia, Alessia Sacchi, Ospedale dell'Alta Val d'Elsa Poggibonsi, Cristina Salvestroni, Ospedale S. Giuseppe Empoli, Sara Zullino, Ospedali Pisani Pisa - Azienda universitaria

### **Umbria**

Gian Carlo Di Renzo, Giorgio Epicoco Azienda Ospedaliera Santa Maria della Misericordia di Perugia; Leonardo Borrello Azienda Ospedaliera Santa Maria di Terni

### **Marche**

Andrea Ciavattini, Sara D'Eusanio AOU - Ospedali Riuniti di Ancona; Filippo Di Prospero Ospedale di Civitanova Marche; Francesco D'Antonio Ospedale Santissima Annunziata Chieti

### **Lazio**

Francesco Antonino Battaglia, Immacolata Marcucci PO Santa Maria Goretti Latina; Marco Bonito Ospedale San Pietro Fatebenefratelli Roma; Daniele Di Mascio Umberto I - Policlinico di Roma; Sergio Ferrazzani Policlinico Universitario Fondazione Agostino Gemelli - Roma; Maria Grazia Frigo Fatebenefratelli San Giovanni Calibita - Isola Tiberina; Giorgio Nicolanti Ospedale Belcolle Viterbo; Giancarlo Paradisi, Maria Rita Pecci Ospedale Fabrizio Spaziani Frosinone

### **Abruzzo**

Fabio Benucci Sant'Omero; Paola Caputo Sulmona; Sandra Di Fabio, Leonardo Di Stefano L'Aquila; Antonio Di Francesco Lanciano; Diego Gazzolo, Marco Liberati Chieti; Anna Marcozzi Teramo; Francesco Mattrullo Vasto; Maurizio Rosati, Gabriella Scorpio Pescara; Giuseppe Ruggeri Avezzano

### **Molise**

Franco Doganiero Ospedale di Campobasso

### **Campania**

Luigi Cobellis, Annunziata Mastrogiovanni Ospedale di Caserta; Maria Vittoria Locci AOU Federico II Napoli

### **Puglia**

Luca Lojudice, Bari - Presidio Mater Dei; Antonio Belpiede Barletta 'Mons. Dimiccoli'; Mariano Cantatore L. Bonomo Andria; Ettore Cincinelli Bari - Policlinico Ginecologia; Aldo D'Aloia, Maurizio De Luca AOU 'OO

RR Foggia' Gin. Uni.; Alessandro Dalfiero Cerignola; Gerardo D'Ambrogio Galatina 'Santa Caterina Novella'; Nicola Del Gaudio Castellaneta; Paolo Demarzo San Severo Teresa Masselli Mascia; Giovanni Di Vagno Bari - San Paolo; Giuseppe Laurelli Casa Sollievo Dalla Sofferenza - S. Giovanni Rotondo; Roberto Lupo Gallipoli; Nicola Macario Altamura; Antonio Malvasi, Bari - Casa Di Cura Santa Maria; Guido Maurizio, Elisabetta Monteduro, Acquaviva 'Miulli'; Andrea Morciano Cardinale G. Panico Di Tricase; Lucio Nichilo Umberto I Corato; Anna Maria Nimis Francavilla Fontana; Antonio Perrone Lecce Vito Fazzi; Elena Rosa Potì Brindisi 'Perrino'; Sabino Santamato Monopoli Putignano; Emilio Stola Taranto; Antonio Tau Scorrano; Mario Vicino Bari - Di Venere; Martino Vinci Martina Franca

### **Basilicata**

Giampiero Adornato Policoro; Francesco Bernasconi Melfi; Alfonso Chiacchio Lagonegro; Sergio Schettini Azienda Ospedaliera Regionale San Carlo - Potenza; Giuseppe Trojano Matera

### **Calabria**

Michele Morelli, Ospedale Annunziata - AO Cosenza; Stefano Palomba Ospedali Riuniti di Reggio Calabria; Morena Rocca Azienda Ospedaliera 'Pugliese Ciaccio' di Catanzaro

### **Sicilia**

Luigi Alio, Giuseppina Orlando ARNAS Civico di Cristina Benfratelli - Palermo; Salvatore Bevilacqua, Fabrizio Quartararo Casa di cura Candela SPA - Palermo; Rocco Billone Civico Partinico e Dei Bianchi - Corleone; Giuseppe Bonanno, Maria Paternò Arezzo - Ragusa, Antonio Bucolo, Umberto I - Siracusa, Claudio Campione, Casa di cura prof. Falcidia - Catania, Giuseppe Canzone, S. Cimino-Termini Imerese, Angelo Caradonna, V. Emanuele II - Castelvetrano, Sebastiano Caudullo e Cosimo Raffone, AO Papardo - Messina, Giovanni Cavallo, PO Maggiore - Modica, Antonio Cianci, Michele Fichera V. Emanuele Rodolico - Catania; Salvatore Corsello, Sergio Di Salvo, Immacolata Schimmenti Casa di cura Villa Serena - Palermo; Rosario D'Anna, AOU G. Martino - Taormina, Maria Rosa D'anna, Buccheri La Ferla - Palermo, Maria Di Costa, Basilotta-Catania, Giuseppe Ettore, ARNAS Garibaldi Nesima - Catania, Giovanni Falzone, Umberto I - Nicosia, Michele Gulizzi e Francesco La Mantia, G. F. Ingrassia - Palermo, Laura Giambanco, S. Antonio Abate - Erice e B. Nagar - Pantelleria, Salvatore Incandela, S. Giovanni di Dio - Agrigento e Giovanni Paolo II - Sciacca; Lilli Maria Klein S. Vincenzo - Enna e Barone Romeo - Patti; Michele La Greca, Venera Mille, M. SS. Addolorata - Biancavilla; Luigi Li Calsi S. Giacomo d'Altovilla - Licata; Emilio Lo Meo, Paolo Scrollo Cannizzaro - Catania; Lucia Lo Presti, Santo Recupero S. Marco (ex V. Emanuele S. Bambino) - Catania e Ospedale Generale - Lentini; Vincenzo Miceli, S. Raffaele Giglio - Cefalù, Maria Pia Militello, S. Marta e S. Venera - Acireale, Alfio Mirella, Istituto clinico Vidimura (ex Casa di cura Gretter e Lucina) - Catania, Umberto Musarra, G. Fogliani - Milazzo e Lipari, Pietro Musso, Abele Ajello - Mazara

*del Vallo*, Michele Palmieri, *V. Emanuele - Gela*, Maria Giovanna Pellegrino, *Basso Ragusa Mario - Militello Val di Catania*, Francesco Pellegriti, *Castiglione Prestianni-Bronte*; Antonio Perino *Villa Sofia - Cervello - Palermo*; Concetta Remigia Pettinato, Angelo Tarascio *Gravina - Caltagirone*; Vincenzo Scattarreggia *Barone Lombardo - Canicatti*; Antonio Schifano *R. Guzzardi - Vittoria*; Calogero Selvaggio *S. Elia - Caltanissetta*; Luigi Triolo *Casa di cure Triolo Zanca SPA - Palermo*; Renato Venezia *P. Giaccone - Palermo*

### Sardegna

Speranza Piredda *Civile Alghero*; Giangavino Peppi *Giovanni Paolo II - Olbia*; Giovanna Pittorra *S. Francesco - Nuoro*; Gianfranco Depau *Nostra Signora della Mercede - Lanusei*; Gianfranco Puggioni *S. Martino - Oristano*; Loredana Pagliara *Nostra Signora di Bonaria - San Gavino*; Giulietta Ibba *CTO - Iglesias*; Caterina Tronci, SS *Trinità - Cagliari*; Giampiero Capobianco, *AOU Sassari*; Alessandra Meloni *Duilio Casula Monserato AOU - Cagliari*; Francesca Palla *S. Michele AO Brotzu - Cagliari*

### REFERENCES

1. Schwartz DA, Graham AL. Potential maternal and infant outcomes from (Wuhan) Coronavirus 2019-nCoV infecting pregnant women: lessons from SARS, MERS, and other human Coronavirus infections. *Viruses*. 2020;12(2):194. Published 2020 Feb 10. doi: 10.3390/v12020194
2. Royal College of Obstetricians and Gynaecologists, Royal College of Midwives, Royal College of Paediatrics and Child Health, Public Health England and Health Protection Scotland. Coronavirus (COVID-19) Infection in Pregnancy. Information for healthcare professionals. Version 9: Published Wednesday 13 May 2020 [cited 2020 May 28]. Available from: [www.rcog.org.uk/globalassets/documents/guidelines/2020-05-13-coronavirus-covid-19-infection-in-pregnancy.pdf](http://www.rcog.org.uk/globalassets/documents/guidelines/2020-05-13-coronavirus-covid-19-infection-in-pregnancy.pdf)
3. Della Gatta AN, Rizzo P, Pilu G, Simonazzi G. COVID-19 during pregnancy: a systematic review of reported cases [published online ahead of print, 2020 Apr 18]. *Am J Obstet Gynecol*. 2020;S0002-9378(20)30438-5. doi: <https://doi.org/10.1016/j.ajog.2020.04.013>
4. Knight M, Bunch K, Vousden N, Morris E, Simpson N, Gale C, O'Brien P, Quigley M, Blocklehurst P, Kurinczuk JJ. Characteristics and outcomes of pregnant women admitted to hospital with confirmed SARS-CoV-2 infection in the UK: national population based cohort study. *BMJ*. 2020;369:m2107. doi: <https://doi.org/10.1136/bmj.m2107>
5. Yan J, Guo J, Fan C, et al. Coronavirus disease 2019 (COVID-19) in pregnant women: A report based on 116 cases [published online ahead of print, 2020 Apr 23]. *Am J Obstet Gynecol*. 2020;S0002-9378(20)30462-2. doi: [10.1016/j.ajog.2020.04.014](https://doi.org/10.1016/j.ajog.2020.04.014)
6. World Health Organization Collaborating Centre for Women's Health University of Birmingham. COVID-19 in pregnancy (PregCOV-19 LRS) [cited 2020 May 28]. Available from: [www.birmingham.ac.uk/research/who-collaborating-centre/pregcov/index.aspx](http://www.birmingham.ac.uk/research/who-collaborating-centre/pregcov/index.aspx).
7. EpiCentro [Internet]. 2020 Feb 20 [cited 2020 May 28]. ItOSS – Italian Obstetric Surveillance System. Italian. Available from: [www.epicentro.iss.it/itosss/](http://www.epicentro.iss.it/itosss/).
8. Campi R, Cartabia M, Miglio D, Bonati M. Certificato di Assistenza al Parto (CedAP) Regione Lombardia. Analisi dell'evento nascita anno 2017 – Laboratorio per la Salute Materno Infantile, Dipartimento di Salute Pubblica, IRCCS – Istituto di Ricerche Farmacologiche Mario Negri Milano: Lombardia Region 2019 [cited 2020 May 28]. Italian. Available from: [www.datilombardia.it/](http://www.datilombardia.it/)
9. Perrone E, Formisano D, Gargano G et al. [Birth in Emilia-Romagna. 2018] Bologna: Emilia-Romagna Region, 2019 [cited 2020 May 28]. Italian. Available from: [www.saperidoc.it/flex/cm/pages/ServeBLOB.php/L/IT/IDPagina/349](http://www.saperidoc.it/flex/cm/pages/ServeBLOB.php/L/IT/IDPagina/349).
10. The COVID-19 Task force of the Department of Infectious Diseases and the IT Service Istituto Superiore di Sanità – Epidemics COVID-19, National update 28th April 2020 [cited 2020 May 28]. Italian. Available from: [www.epicentro.iss.it/coronavirus/bollettino/Bollettino-sorveglianza-integrata-COVID-19\\_28-aprile-2020.pdf](http://www.epicentro.iss.it/coronavirus/bollettino/Bollettino-sorveglianza-integrata-COVID-19_28-aprile-2020.pdf).
11. Yang Z, Wang M, Zhu Z, Liu Y. Coronavirus disease 2019 (COVID-19) and pregnancy: a systematic review [published online ahead of print, 2020 Apr 30]. *J Matern Fetal Neonatal Med*. 2020;1-4. doi: [10.1080/14767058.2020.1759541](https://doi.org/10.1080/14767058.2020.1759541)
12. Arabi S, Vaseghi G, Heidari Z, et al. Clinical characteristics of COVID-19 infection in pregnant women: a systematic review and meta-analysis. *medRxiv* 2020.04.05.20053983 [preprint]. 2020 [cited 2020 May 28]. Available from: <https://doi.org/10.1101/2020.04.05.20053983>.
13. Poon LC, Yang H, Dumont S, et al. ISUOG Interim Guidance on coronavirus disease 2019 (COVID-19) during pregnancy and puerperium: information for healthcare professionals - an update [published online ahead of print, 2020 May 1]. *Ultrasound Obstet Gynecol*. 2020;10.1002/uog.22061. doi: [10.1002/uog.22061](https://doi.org/10.1002/uog.22061)
14. World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected – Interim guidance – 13 March 2020 [cited 2020 May 28]. Available from: [www.who.int/docs/default-source/coronavirus/clinical-management-of-novel-cov.pdf](http://www.who.int/docs/default-source/coronavirus/clinical-management-of-novel-cov.pdf).
15. Dong L, Tian J, He S, et al. Possible vertical transmission of SARS-CoV-2 from an infected mother to her newborn [published online ahead of print, 2020 Mar 26]. *JAMA*. 2020;323(18):1846-8. doi: [10.1001/jama.2020.4621](https://doi.org/10.1001/jama.2020.4621)
16. Patanè L, Morotti D, Giunta MR, et al. Vertical transmission of COVID-19: SARS-CoV-2 on the fetal side of the placenta in pregnancies with COVID-19 positive mothers and neonates at birth. *Am J Obstet Gynecol MFM*. 2020;100145. doi: [10.1016/j.ajogmf.2020.100145](https://doi.org/10.1016/j.ajogmf.2020.100145)
17. Costantine MM, Landon MB, Saade GR. Protection by exclusion: another missed opportunity to include pregnant women in research during the coronavirus disease 2019 (COVID-19) pandemic [published online ahead of

- print, 2020 Apr 24]. *Obstet Gynecol*. 2020. doi: 10.1097/AOG.0000000000003924
18. European Medicines Agency [Internet]. EMA/275870/2020 [cited 2020 May 28]. Global regulators commit to cooperate on observational research in the context of COVID-19. Available from: [www.ema.europa.eu/en/news/global-regulators-commit-cooperate-observational-research-context-covid-19](http://www.ema.europa.eu/en/news/global-regulators-commit-cooperate-observational-research-context-covid-19).